INS and type 1 diabetes mellitus: As T1D affects around 8.4 million individuals worldwide and its prevalence is expected to double in the next two decades2, it carries a considerable personal and societal burden, with adherence to a lifelong insulin requirement, a 10-year shortened life expectancy3 and a per-patient cumulative economic burden close to US$500,000 (ref. 4).